SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 29
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 26 27 28 29
|
presentations:
1 to
50 of
1418
|
Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1 (ABSTRACT
115)
Russ P. Carstens
Merck & Co., Inc.
Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI (ABSTRACT
116)
Carl J. Fichtenbaum
University of Cincinnati, Cincinnati, OH, USA
VH3810109 (N6LS) in Adults With HIV-1 Who Are ART-Naive-: Phase IIa BANNER Efficacy Data (ABSTRACT
117)
Jan Losos
ViiV Healthcare, Research Triangle Park, NC, USA
A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236 (ABSTRACT
118)
Athe Tsibris
Brigham and Women's Hospital, Boston, MA, USA
QUESTIONS AND ANSWERS (Part 1)
Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial (ABSTRACT
119)
Babafemi Taiwo
Northwestern University, Chicago, IL, USA
Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab (ABSTRACT
120)
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies (ABSTRACT
121)
Boris D. Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results (ABSTRACT
122)
Nicholas Paton
London School of Hygiene & Tropical Medicine, London, UK
QUESTIONS AND ANSWERS (Part 2)
Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women (ABSTRACT
123)
Tanuja N. Gengiah
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
Final Results of ANRS 174 DOXYVAC: A Randomized Trial to Prevent STI in MSM on PrEP (ABSTRACT
124)
Jean-Michel G. Molina
University of Paris-Est, Paris, France
Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension (ABSTRACT
125)
Annie Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
Doxycycline PEP: High Uptake and Significant Decline in STIs After Clinical Implementation (ABSTRACT
126)
Hyman M. Scott
San Francisco Department of Public Health, San Francisco, CA, USA
QUESTIONS AND ANSWERS (Part 1)
Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco (ABSTRACT
127)
Madeline Sankaran
San Francisco Department of Public Health, San Francisco, CA, USA
Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083 (ABSTRACT
128)
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV (ABSTRACT
129)
Gillian Gillespie
Merck & Co., Inc.,
Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval (ABSTRACT
130)
Kelong Han
GSK
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 (ABSTRACT
131)
Meredith Clement
Louisiana State University, New Orleans, LA, USA
QUESTIONS AND ANSWERS (Part 2)
Safety Profile and Immunogenicity of a Phase I Clinical Trial Using Germline-Targeting Trimer GT1.1 (ABSTRACT
100)
Karlijn van der Straten
Academic Medical Center, Amsterdam, Netherlands
Vaccine Combining Slow-Delivery and Follicle-Targeting Improve Humoral and Germinal Center Responses (ABSTRACT
101)
Y. Jason Zhang
Massachusetts Institute of Technology, Cambridge, MA, USA
Multi-Specificity Is a Common Trait of HIV-1 Broad Neutralizing Capacity (ABSTRACT
102)
Alexandra Trkola
University of Zurich, Zurich, Switzerland
CD4 Binding Site Glycan-Deficient SHIVs Elicit Broadly Neutralizing Antibodies in Rhesus Macaques (ABSTRACT
103)
Daniel J. Morris
University of Pennsylvania, Philadelphia, PA, USA
QUESTIONS AND ANSWERS (Part 1)
MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques (ABSTRACT
104)
Philippe Rascle
Duke University, Durham, NC, USA
[18F]F-AraG PET Imaging Reveals Unique Tissue T-Cell Activation Patterns Across HIV Infection States (ABSTRACT
105)
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI (ABSTRACT
106)
Preethi Krishnan
AbbVie, Inc, North Chicago, IL, USA
Live Single-Cycle SARS-CoV-2 Vaccine Elicits High Protection and Sterilizing Immunity (ABSTRACT
107)
Fabian Otte
University of Basel, Basel, Switzerland
QUESTIONS AND ANSWERS (Part 2)
Assessing the Contribution of Glial Activation to Cognitive Control and Declarative Memory in PWH (ABSTRACT
109)
Leah H. Rubin
The Johns Hopkins University, Baltimore, MD, USA
Associations Between Depressive Symptom Severity and Incident Stroke Among People With HIV (ABSTRACT
110)
Jimmy Ma
University of Washington, Seattle, WA, USA
Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection (ABSTRACT
111)
Meg Wilson
University of California San Francisco, San Francisco, CA, USA
Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation (ABSTRACT
112)
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
QUESTIONS AND ANSWERS (Part 1)
HIV Transcription Persists in the Brain of People With HIV and Viral Suppression (ABSTRACT
113)
Melissa J. Churchill
RMIT University, Melbourne, Australia
Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH (ABSTRACT
114)
Shelli Farhadian
Yale University, New Haven, CT, USA
Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies (ABSTRACT
108)
Sharon R. Lewin
University of Melbourne, Melbourne, Australia
QUESTIONS AND ANSWERS (Part 2)
COVID Incidence and Severity in Persons With Reinfection vs Post-Vaccination Breakthrough Infection (ABSTRACT
132)
Adeel A. Butt
Weill Cornell Medicine, New York, NY, USA
MRNA Vaccine Versus Hybrid Immunity Against COVID-19 Among People With HIV During Omicron Wave (ABSTRACT
133)
Asa Tapley
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
|
<< first | < prev
page:
of 29
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 26 27 28 29
|
presentations:
1 to
50 of
1418
|
